Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
Description of Invention:
New hybrid nanomaterials that can be used as multimodal imaging contrast agents. These hybrid nanomaterials produce highly efficient MRI contrast agents that can be bound to a targeting group that acts to direct the contrast agent to a specific organ or cells expressing specific molecular signals, such as certain cancer cells.
Can be conjugated to target moieties to make them specific for diseased states such as tumor and inflammation sites. In some designs the contrast agent can be bound to a group that increases:
· The size
· Circulation half-life
· Enhance the solubility of the contrast agent in a specific solvent
· Comprising of a luminophore for the use in detecting the presence of the contrast agent via an optical technique.
Exhibit several orders of magnitude larger relaxivities than those of existing Gd- and Mn-based small-molecule contrast agents, therefore more easily detected. Positive image enhancement compared to negative image enhancement by iron oxide-based contrast agents
Disease-specific imaging and early diagnosis of cancer and inflammatory
disease such as rheumatoid arthritis